Business
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company
About this update from Cytomed Therapeutics Limited
[{"type":"text","content":"SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) (\"CytoMed\" or \"the Company\"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced its exclusively licensed induced pluripotent stem call (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).\"We're thrilled to strengthen our existing suite of patents,\" said Peter Choo, Chairman of CytoMed. \"Now this novel iPSC-based technology has been granted patent in China and Japan (where the iPSC technology was pioneered in 2006). Such progress further expands the Company's current patent portfolio to three countries, consisting of and including patents granted in the US and China for our licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology which is expected to start phase I clinical trial in Singapore soon.\"The granted patent is titled \"Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells\" under Patent No. ZL201880022790.X, published as CN 110691844 B. CytoMed's new patent specifically covers tech to derive novel synthetic γδ NKT cells for the treatment of a wide range of cancers, such as hematological malignancies and solid tumors.Immune cells like γδ NKT cells and natural killer (NK) cells are extremely valuable as a viable cancer treatment due to their ability to express an array of built-in receptors that can naturally recognize stress-induced cancer antigens.Using the patented iPSC technology, CytoMed can generate novel types of synthetic hybrid immune cells, γδ NKT cells, which can express receptors of both γδ T cells and NK cells without the use of genetic modification or viral vectors. As a result, the company can use this as an allogeneic cell source to become a potential \"off-the-shelf\" cell therapy capable of helping a large number of cancer patients.The assets continue its preclinical development and CytoMed maintains an exclusive, worldwide license to use this patented technology as stated under its previously disclosed licensing agreement from June 1, 2018.For more information about the company's services, latest news, and ongoing initiatives, visit http...